Stocktoria
NORTHWEST BIOTHERAPEUTICS INC NWBO
NORTHWEST BIOTHERAPEUTICS INC (NWBO) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $1.4M at a -4365.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1965 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
| IGC | IGC Pharma, Inc. | 3/9 | — | — | — |
| VTGN | Vistagen Therapeutics, Inc. | 2/9 | — | — | — |
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
About NORTHWEST BIOTHERAPEUTICS INC
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
FAQ
Is NWBO financially healthy?
NORTHWEST BIOTHERAPEUTICS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does NWBO pay a dividend?
No, NORTHWEST BIOTHERAPEUTICS INC does not currently pay a dividend.
How profitable is NWBO?
In FY2025, NORTHWEST BIOTHERAPEUTICS INC had a net margin of -4365.9%.
What is the analyst price target for NWBO?
The average Wall-Street price target for NORTHWEST BIOTHERAPEUTICS INC is $1.00, about 426.3% above the recent price, from 1 analysts.
Is NWBO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NORTHWEST BIOTHERAPEUTICS INC: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.